Association of Vaccination With Symptomatic SARS-CoV-2 Infection by Time Since Vaccination and Delta Predominance | Vaccination | JN Learning | AMA Ed Hub [Skip to Content]
[Skip to Content Landing]

Association of COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection by Time Since Vaccination and Delta Variant Predominance

Educational Objective
To identify the key insights or developments described in this article
Key Points

Question  How does the association between prior COVID-19 vaccination and symptomatic SARS-CoV-2 infection change with time since vaccination and the SARS-CoV-2 Delta variant?

Findings  In this test-negative, case-control study that included 1 634 271 tests from symptomatic adults, the odds ratio for prior mRNA vaccination and SARS-CoV-2 test positivity was lower before than during Delta variant predominance. The attenuation in effect size related to time since vaccination was greater than the attenuation related to the Delta variant.

Meaning  The findings are consistent with a steady decline in estimated mRNA vaccine effectiveness over time, separate from variant-specific differences in protection.

Abstract

Importance  Monitoring COVID-19 vaccine performance over time since vaccination and against emerging variants informs control measures and vaccine policies.

Objective  To estimate the associations between symptomatic SARS-CoV-2 infection and receipt of BNT162b2, mRNA-1273, and Ad26.COV2.S by day since vaccination before and during Delta variant predominance (pre-Delta period: March 13-May 29, 2021; Delta period: July 18-October 17, 2021).

Design, Setting, and Participants  Test-negative, case-control design with data from 6884 US COVID-19 testing sites in the pharmacy-based Increasing Community Access to Testing platform. This study included 1 634 271 laboratory-based SARS-CoV-2 nucleic acid amplification tests (NAATs) from adults 20 years and older and 180 112 NAATs from adolescents 12 to 19 years old with COVID-19–like illness from March 13 to October 17, 2021.

Exposures  COVID-19 vaccination (1 Ad26.COV2.S dose or 2 mRNA doses) 14 or more days prior.

Main Outcomes and Measures  Association between symptomatic infection and prior vaccination measured using the odds ratio (OR) from spline-based multivariable logistic regression.

Results  The analysis included 390 762 test-positive cases (21.5%) and 1 423 621 test-negative controls (78.5%) (59.9% were 20-44 years old; 9.9% were 12-19 years old; 58.9% were female; 71.8% were White). Among adults 20 years and older, the BNT162b2 mean OR for days 14 to 60 after a second dose (initial OR) was lower during the pre-Delta period (0.10 [95% CI, 0.09-0.11]) than during the Delta period (0.16 [95% CI, 0.16-0.17]) and increased with time since vaccination (per-month change in OR, pre-Delta: 0.04 [95% CI, 0.02-0.05]; Delta: 0.03 [95% CI, 0.02-0.03]). The initial mRNA-1273 OR was 0.05 (95% CI, 0.04-0.05) during the pre-Delta period, 0.10 (95% CI, 0.10-0.11) during the Delta period, and increased with time (per-month change in OR, pre-Delta: 0.02 [95% CI, 0.005-0.03]; Delta: 0.03 [95% CI, 0.03-0.04]). The Ad26.COV2.S initial OR was 0.42 (95% CI, 0.37-0.47) during the pre-Delta period and 0.62 (95% CI, 0.58-0.65) during the Delta period and did not significantly increase with time since vaccination. Among adolescents, the BNT162b2 initial OR during the Delta period was 0.06 (95% CI, 0.05-0.06) among 12- to 15-year-olds, increasing by 0.02 (95% CI, 0.01-0.03) per month, and 0.10 (95% CI, 0.09-0.11) among 16- to 19-year-olds, increasing by 0.04 (95% CI, 0.03-0.06) per month.

Conclusions and Relevance  Among adults, the OR for the association between symptomatic SARS-CoV-2 infection and COVID-19 vaccination (as an estimate of vaccine effectiveness) was higher during Delta variant predominance, suggesting lower protection. For mRNA vaccination, the steady increase in OR by month since vaccination was consistent with attenuation of estimated effectiveness over time; attenuation related to time was greater than that related to variant.

Sign in to take quiz and track your certificates

Buy This Activity

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.

Article Information

Corresponding Author: Amadea Britton, MD, COVID-19 Response, US Centers for Disease Control and Prevention, 1600 Clifton Rd, Mailstop H24-6, Atlanta, GA 30329 (LTO7@cdc.gov).

Accepted for Publication: February 3, 2022.

Published Online: February 14, 2022. doi:10.1001/jama.2022.2068

Author Contributions: Drs Britton and Shang had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Drs Britton and Fleming-Dutra contributed equally to this article. Drs Verani and Schrag contributed equally to this article.

Concept and design: Britton, Fleming-Dutra, Shang, Ajani, Schrag, Verani.

Acquisition, analysis, or interpretation of data: All authors.

Drafting of the manuscript: Britton, Fleming-Dutra, Shang, Dorji, Schrag, Verani.

Critical revision of the manuscript for important intellectual content: All authors.

Statistical analysis: Britton, Shang, Dorji, Derado, Accorsi.

Obtained funding: Miller.

Administrative, technical, or material support: Britton, Fleming-Dutra, Smith, Ajani, Miller, Schrag, Verani.

Supervision: Fleming-Dutra, Miller, Schrag, Verani.

Conflict of Interest Disclosures: None reported.

Funding/Support: Funding for the Increasing Community Access to Testing platform is provided by the US Department of Health and Human Services. Funding for this analysis was provided by the Centers for Disease Control and Prevention (CDC).

Role of the Funder/Sponsor: The CDC was involved in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, and approval of the manuscript; and decision to submit the manuscript for publication. The CDC controlled publication decisions.

Disclaimer: The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the CDC.

References
1.
Polack  FP , Thomas  SJ , Kitchin  N ,  et al; C4591001 Clinical Trial Group.  Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine.   N Engl J Med. 2020;383(27):2603-2615. doi:10.1056/NEJMoa2034577PubMedGoogle ScholarCrossref
2.
Baden  LR , El Sahly  HM , Essink  B ,  et al; COVE Study Group.  Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine.   N Engl J Med. 2021;384(5):403-416. doi:10.1056/NEJMoa2035389PubMedGoogle ScholarCrossref
3.
Sadoff  J , Gray  G , Vandebosch  A ,  et al; ENSEMBLE Study Group.  Safety and efficacy of single-dose Ad26.COV2.S vaccine against COVID-19.   N Engl J Med. 2021;384(23):2187-2201. doi:10.1056/NEJMoa2101544PubMedGoogle ScholarCrossref
4.
Pilishvili  T , Gierke  R , Fleming-Dutra  KE ,  et al; Vaccine Effectiveness Among Healthcare Personnel Study Team.  Effectiveness of mRNA COVID-19 vaccine among US health care personnel.   N Engl J Med. 2021;385(25):e90. doi:10.1056/NEJMoa2106599PubMedGoogle Scholar
5.
Thompson  MG , Burgess  JL , Naleway  AL ,  et al.  Prevention and attenuation of COVID-19 with the BNT162b2 and mRNA-1273 vaccines.   N Engl J Med. 2021;385(4):320-329. doi:10.1056/NEJMoa2107058PubMedGoogle ScholarCrossref
6.
Corchado-Garcia  J , Zemmour  D , Hughes  T ,  et al.  Analysis of the effectiveness of the Ad26.COV2.S adenoviral vector vaccine for preventing COVID-19.   JAMA Netw Open. 2021;4(11):e2132540-e2132540. doi:10.1001/jamanetworkopen.2021.32540PubMedGoogle ScholarCrossref
7.
Chemaitelly  H , Tang  P , Hasan  MR ,  et al.  Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar.   N Engl J Med. 2021;385(24):e83. doi:10.1056/NEJMoa2114114PubMedGoogle Scholar
8.
Martínez-Baz  I , Trobajo-Sanmartín  C , Miqueleiz  A ,  et al; Working Group for the Study of COVID-19 in Navarre; Investigators, other members of the Working Group for the Study of COVID-19 in Navarre.  Product-specific COVID-19 vaccine effectiveness against secondary infection in close contacts, Navarre, Spain, April to August 2021.   Euro Surveill. 2021;26(39):2100894. doi:10.2807/1560-7917.ES.2021.26.39.2100894PubMedGoogle Scholar
9.
Tartof  SY , Slezak  JM , Fischer  H ,  et al.  Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study.   Lancet. 2021;398(10309):1407-1416. doi:10.1016/S0140-6736(21)02183-8PubMedGoogle ScholarCrossref
10.
Thomas  SJ , Moreira  ED  Jr , Kitchin  N ,  et al; C4591001 Clinical Trial Group.  Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine through 6 months.   N Engl J Med. 2021;385(19):1761-1773. doi:10.1056/NEJMoa2110345PubMedGoogle ScholarCrossref
11.
Bruxvoort  KJ , Sy  LS , Qian  L ,  et al.  Effectiveness of mRNA-1273 against Delta, Mu, and other emerging variants of SARS-CoV-2: test negative case-control study.   BMJ. 2021;375:e068848. doi:10.1136/bmj-2021-068848PubMedGoogle Scholar
12.
Lopez Bernal  J , Andrews  N , Gower  C ,  et al.  Effectiveness of COVID-19 vaccines against the B.1.617.2 (Delta) variant.   N Engl J Med. 2021;385(7):585-594. doi:10.1056/NEJMoa2108891PubMedGoogle ScholarCrossref
13.
Centers for Disease Control and Prevention. COVID data tracker: variant proportions. Accessed September 7, 2021. https://covid.cdc.gov/covid-data-tracker/#variant-proportions
14.
Frenck  RW  Jr , Klein  NP , Kitchin  N ,  et al; C4591001 Clinical Trial Group.  Safety, immunogenicity, and efficacy of the BNT162b2 COVID-19 vaccine in adolescents.   N Engl J Med. 2021;385(3):239-250. doi:10.1056/NEJMoa2107456PubMedGoogle ScholarCrossref
15.
Food and Drug Administration. Pfizer-BioNTech COVID-19 vaccine EUA letter of authorization. Accessed October 4, 2021. https://www.fda.gov/media/144412/download
16.
Miller  MF , Shi  M , Motsinger-Reif  A , Weinberg  CR , Miller  JD , Nichols  E .  Community-based testing sites for SARS-CoV-2: United States, March 2020-November 2021.   MMWR Morb Mortal Wkly Rep. 2021;70(49):1706-1711. doi:10.15585/mmwr.mm7049a3PubMedGoogle ScholarCrossref
17.
Accorsi  EK , Britton  A , Fleming-Dutra  KE ,  et al.  Association between 3 doses of mRNA COVID-19 vaccine and symptomatic infection caused by the SARS-CoV-2 Omicron and Delta variants.   JAMA. Published January 21, 2022. doi:10.1001/jama.2022.0470PubMedGoogle Scholar
18.
Centers for Disease Control and Prevention. 07/31/2020: Lab advisory: update on COVID-19 laboratory reporting requirements. Accessed January 11, 2022. https://www.cdc.gov/csels/dls/locs/2020/update-on-covid-19-reporting-requirements.html
19.
Agency for Toxic Substances and Disease Registry. CDC/ATSDR Social Vulnerability Index. Accessed September 24, 2021. https://www.atsdr.cdc.gov/placeandhealth/svi/index.html
20.
Chua  H , Feng  S , Lewnard  JA ,  et al.  The use of test-negative controls to monitor vaccine effectiveness: a systematic review of methodology.   Epidemiology. 2020;31(1):43-64. doi:10.1097/EDE.0000000000001116PubMedGoogle ScholarCrossref
21.
US Food and Drug Administration. Moderna COVID-19 vaccine letter of authorization. Accessed October 4, 2021. https://www.fda.gov/media/144636/download
22.
US Food and Drug Administration. Janssen COVID-19 vaccine EUA letter of authorization. Accessed October 4, 2021. https://www.fda.gov/media/146303/download
23.
Centers for Disease Control and Prevention. Interim public health recommendations for fully vaccinated people. Updates as of May 28, 2021. Accessed September 24, 2021. https://web.archive.org/web/20210530040439/https://www.cdc.gov/coronavirus/2019-ncov/vaccines/fully-vaccinated-guidance.html
24.
Centers for Disease Control and Prevention. Interim public health recommendations for fully vaccinated people. Updated July 27, 2021. Accessed January 10, 2022. https://web.archive.org/web/20210727235224/https:/www.cdc.gov/coronavirus/2019-ncov/vaccines/fully-vaccinated-guidance.html
25.
Centers for Disease Control and Prevention. US state and territorial public mask mandates from April 10, 2020, through August 15, 2021, by county by day. Accessed October 4, 2021. https://data.cdc.gov/Policy-Surveillance/U-S-State-and-Territorial-Public-Mask-Mandates-Fro/62d6-pm5i
26.
Centers for Disease Control and Prevention. Interim clinical considerations for use of COVID-19 vaccines currently approved or authorized in the United States. Accessed November 5, 2021. https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html
27.
Keehner  J , Horton  LE , Binkin  NJ ,  et al; SEARCH Alliance.  Resurgence of SARS-CoV-2 infection in a highly vaccinated health system workforce.   N Engl J Med. 2021;385(14):1330-1332. doi:10.1056/NEJMc2112981PubMedGoogle ScholarCrossref
28.
Pouwels  KB , Pritchard  E , Matthews  PC ,  et al.  Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK.   Nat Med. 2021;27(12):2127-2135. doi:10.1038/s41591-021-01548-7PubMedGoogle ScholarCrossref
29.
Tabak  YP , Sun  X , Brennan  TA , Chaguturu  SK .  Incidence and estimated vaccine effectiveness against symptomatic SARS-CoV-2 infection among persons tested in US retail locations, May 1 to August 7, 2021.   JAMA Netw Open. 2021;4(12):e2143346-e2143346. doi:10.1001/jamanetworkopen.2021.43346PubMedGoogle ScholarCrossref
30.
Fowlkes  A , Gaglani  M , Groover  K , Thiese  MS , Tyner  H , Ellingson  K ; HEROES-RECOVER Cohorts.  Effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infection among frontline workers before and during B.1.617.2 (Delta) variant predominance: eight US locations, December 2020-August 2021.   MMWR Morb Mortal Wkly Rep. 2021;70(34):1167-1169. doi:10.15585/mmwr.mm7034e4PubMedGoogle ScholarCrossref
31.
Rosenberg  ES , Dorabawila  V , Easton  D ,  et al.  COVID-19 vaccine effectiveness in New York State.   N Engl J Med. 2022;386(2):116-127. doi:10.1056/NEJMoa2116063PubMedGoogle ScholarCrossref
32.
Sheikh  A , McMenamin  J , Taylor  B , Robertson  C ; Public Health Scotland and the EAVE II Collaborators.  SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness.   Lancet. 2021;397(10293):2461-2462. doi:10.1016/S0140-6736(21)01358-1PubMedGoogle ScholarCrossref
33.
Tang  P , Hasan  MR , Chemaitelly  H ,  et al.  BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar.   Nat Med. 2021;27(12):2136-2143. doi:10.1038/s41591-021-01583-4PubMedGoogle ScholarCrossref
34.
Grannis  SJ , Rowley  EA , Ong  TC ,  et al; VISION Network.  Interim estimates of COVID-19 vaccine effectiveness against COVID-19-associated emergency department or urgent care clinic encounters and hospitalizations among adults during SARS-CoV-2 B.1.617.2 (Delta) variant predominance: nine states, June-August 2021.   MMWR Morb Mortal Wkly Rep. 2021;70(37):1291-1293. doi:10.15585/mmwr.mm7037e2PubMedGoogle ScholarCrossref
35.
Glatman-Freedman  A , Hershkovitz  Y , Kaufman  Z , Dichtiar  R , Keinan-Boker  L , Bromberg  M .  Effectiveness of BNT162b2 vaccine in adolescents during outbreak of SARS-CoV-2 Delta variant infection, Israel, 2021.   Emerg Infect Dis. 2021;27(11):2919-2922. doi:10.3201/eid2711.211886PubMedGoogle ScholarCrossref
36.
Reis  BY , Barda  N , Leshchinsky  M ,  et al.  Effectiveness of BNT162b2 vaccine against Delta variant in adolescents.   N Engl J Med. 2021;385(22):2101-2103. doi:10.1056/NEJMc2114290PubMedGoogle ScholarCrossref
37.
Lutrick  K , Rivers  P , Yoo  YM ,  et al.  Interim estimate of vaccine effectiveness of BNT162b2 (Pfizer-BioNTech) vaccine in preventing SARS-CoV-2 infection among adolescents aged 12-17 years: Arizona, July-December 2021.   MMWR Morb Mortal Wkly Rep. 2021;70(5152):1761-1765. doi:10.15585/mmwr.mm705152a2PubMedGoogle ScholarCrossref
38.
Jackson  ML , Phillips  CH , Benoit  J ,  et al.  The impact of selection bias on vaccine effectiveness estimates from test-negative studies.   Vaccine. 2018;36(5):751-757. doi:10.1016/j.vaccine.2017.12.022PubMedGoogle ScholarCrossref
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_Multimedia_LoginSubscribe_Purchase
Close
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_Multimedia_LoginSubscribe_Purchase
Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close

Name Your Search

Save Search
Close
With a personal account, you can:
  • Track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
jn-learning_Modal_SaveSearch_NoAccess_Purchase
Close

Lookup An Activity

or

Close

My Saved Searches

You currently have no searches saved.

Close

My Saved Courses

You currently have no courses saved.

Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close